Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II
申请人:Heymans Francoise
公开号:US20050075345A1
公开(公告)日:2005-04-07
The present invention relates to a compound of the following formula (I) and pharmaceutical compositions containing the compound of formula (I):
wherein D, Y, A, B, p, q, W and R have the same meanings as defined in the specification.
Design of new potent and selective secretory phospholipase A2 inhibitors. 6-Synthesis, structure–activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives
The group IIA human non-pancreatic secretory phospholipase A(2) (hnp-sPLA(2)) is one of the enzymes implied in the inflammatory process. In the course of our work on inhibitors of this enzyme we investigated the influence of rigidity of the piperazine region on the biological activity. Several modifications were explored. Various linkers, such as amide, urea, carbamate, or alkoxyphenyl were inserted between the piperazine and the lipophilic chain. Also, modification of the piperazine core to incorporate carbonyl groups was studied. In an in vitro fluorimetric assay using the human GIIA (HPLA(2)) and porcine pancreatic GIB enzymes, compound 60a (Y = phenoxy, R = C18H37, Z= CH2) had the optimal activity with an IC50 = 30 nM on HPLA(2). By means of molecular modelling we attempted to get informations towards comprehension of differences in activity. (C) 2010 Elsevier Ltd. All rights reserved.